Compare Amphastar Pharmaceuticals Inc (AMPH) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Plby Group Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while Plby Group Inc trades at $1.16 (market cap $134.09M). The key difference: Amphastar Pharmaceuticals Inc is far larger — about 6.2× Plby Group Inc's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | PLBY | |
|---|---|---|
Market Cap | $826.08M | $134.09M |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $2.71 |
52-Week Low | $16.87 | $1.14 |
Enterprise Value | $1.22B | $281.90M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
PLBY trades at $1.16 with no recent price movement, showing technical bearish signals despite oversold RSI readings. The company has shown improving fundamentals with revenue stabilizing around $120-122 million and narrowing losses from -$278M in 2022 to -$13M in 2025. Recent positive developments include Russell index inclusion and a strategic share repurchase program. Operating cash flow turned positive in 2025 after years of negative performance, though the company maintains high debt levels with a debt-to-asset ratio of 59.52%.
While PLBY shows operational improvement and strong analyst support (75% buy ratings), significant risks remain including negative shareholder equity, high debt burden, and inconsistent earnings performance. The stock presents a turnaround opportunity if management can sustain EBITDA growth and debt reduction, but requires careful monitoring of cash flow sustainability and licensing revenue stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
